Baili Tianheng (688506.SH): Lunkangilongtuo monoclonal antibody/ Yizekang (BL-B01D1/iza-bren) esophageal cancer indication for approval of marketing application approved.

Zhtng Cijng APP News, Biltinhng (688506.SH) announced that, recently, the company has received the "Drug Registration Certificate" from the National Medical Products Administration, approving the company's independently developed global first-in-class, new concept, globally first and only approved EGFRHER3 dual-antibody ADC lunkangyilongtuodankang/yzkng (BL-B01D1/iza-bren) for the second-line indication of advanced esophageal cancer. Market approval for the application.